Status:
UNKNOWN
The ALA, DHA and EPA Esters in the Prevention of Cardiovascular Diseases.
Lead Sponsor:
Wroclaw Medical University
Conditions:
Fatty Acids
Alpha-Linolenic Acid
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
Essential polyunsaturated fatty acids (EFAs) have a significant impact on human health, even before birth. Their supplementation is recommended at all ages, especially in people with cardiolovascular ...
Detailed Description
Supplementation of essential polyunsaturated fatty acids (EFAs) in patients is recommended by cardiological, diabetic, hypertensive and gynecological societies. The project aims to demonstrate the ben...
Eligibility Criteria
Inclusion
- adults of both sexes in good general condition.
Exclusion
- pregnancy, acute diseases or uncontrolled / unchecked chronic diseases, indications for absolute treatment with lipid-lowering drugs or its modification, insulin-dependent diabetes mellitus, liver diseases, use of warfarin or heparin.
Key Trial Info
Start Date :
December 9 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 30 2022
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT04743050
Start Date
December 9 2020
End Date
June 30 2022
Last Update
February 8 2021
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Family Medicine at Wroclaw Medical University
Wroclaw, Dolny Slask, Poland, 51-141
2
Model Practice of a Family Doctor Maria Bujnowska-Fedak
Wroclaw, Dolny Slask, Poland, 53-603
3
TIGmed Private Medical Practice
Wroclaw, Dolny Slask, Poland, 53-603